PCSK9 and age-related macular degeneration: In its recent annual report (28), the agency published aggregated reports for MPs in some therapeutic areas of interest, such as chronic hepatitis C, age-related macular degeneration, family hypercholesterolemia (PCSK9), and non-small lung cell cancer ALK-inhibitors.